News | July 02, 2024
Abbott and YRGCARE inaugurate new outreach centers in India
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated
